NantOmics to Present Potential Treatment Options for SCLC Patients with Multiplexed Clinical Proteomic Testing at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting
CHICAGO--(BUSINESS WIRE)-- NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks ecosystem of companies, will present findings on potential treatment options for small-cell lung cancer (SCLC) patients with multiplexed clinical proteomic testing during the lung cancer—non-small cell local-regional/small cell/other thoracic cancers session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event bringing together 30,000 oncology professionals from June 1-5, 2018 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #7147 during the event.
“We look forward to sharing insights on protein targets of multiple approved and investigational therapies to identify treatment options for patients with SCLC,” said Patrick Soon-Shiong, MD, founder of NantWorks. “Platinum doublet therapy has been a standard treatment for patients with SCLC, yet patients typically survive less than one year. Our study brings us closer to potentially identifying SCLC treatments based on individuals’ responses to targeted protein therapy.”
Identifying treatment options for SCLC patients with multiplexed clinical proteomic testing, Abstract #8574
WHO: NantOmics, LLC
WHAT: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
WHEN: June 3, 8:00-11:30 AM CST
WHERE: Hall A, McCormick Place
In an effort to identify treatment options for patients with SCLC, this study was conducted to assess the proportions of patients who would be likely to respond to single-agent chemotherapy or clinical trials of certain agents targeting the proteins DLL3, CD56 or TROP2. Archived tumor samples from 88 SCLC patients were microdissected and solubilized for proteomic quantification of 58 therapeutically relevant biomarkers. In each sample, quantities of tumor protein were compared with pre-defined thresholds based on evidence from clinical studies or on quantification limits of proteomic assays. Prevalences and protein expression levels in SCLC were compared with those of other cancer indications analyzed in the same clinical laboratory. The study revealed that in patients with SCLC, clinical proteomics identified protein targets of multiple approved and investigational therapies.
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular analysis company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
Source: NantOmics, LLC